Page 361 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 361
LP44 PHAGOCYTOSIS: HOW THE BEGINNING PROGRAMS THE LATE BREAKER ePOSTERS
LP45 END IN THE DAMAGED LIVER
Lara Campana*, Antonella Pellicoro, Rebecca Aucott, Stephen Greenalgh,
LP46 Steven Anderton, John P. Iredale, The United Kingdom
LP47 THE HEPATITIS B VIRUS (HBV) SURFACE ANTIGEN
LP48 IMPEDES HEPADNAVIRAL REPLICATION-DEPENDENT
LP49 INTERFERON RESPONSES IN A HBV TRANSGENIC MOUSE
MODEL
Catherine I. Real, Mengji Lu, Markus Hossbach, Jochen Deckert,
Kerstin Jahn-Hofmann, Ludger M. Ickenstein, Matthias J. John,
Martin Trippler, Kathrin Gibbert, Ulf Dittmer, Hans-Peter Vornlocher,
Reinhold Schirmbeck, Guido Gerken, Joerg F. Schlaak, Ruth Broering*,
Germany
OCCULT HBV IS HIGHLY PREVALENT IN PATIENTS WITH
INTRAHEPATIC CHOLANGIOCARCINOMA AND IT IS
DETECTED AS BOTH FREE EPISOMAL AND INTEGRATED
DNA
Teresa Pollicino*, Cristina Musolino, Gianluca Tripodi, Marika Lanza,
Giuseppina Raffa, Carlo Saitta, Salvatore Benfatto, Concetta Beninati,
Giuseppe Navarra, Pietro Invernizzi, Domenico Alvaro,
Giovanni Raimondo, Italy
EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE TO
PREVENT VERTICAL TRANSMISSION IN MOTHERS WITH
LAMIVUDINE-RESISTANT HBV
Jinfeng Liu*, Jing Wang, Furong Cao, Taotao Yan, Caijing Qi,
Tianyan Chen,Yingren Zhao, China
SVR12 RESULTS AFTER 12-WEEKS BOCEPREVIR,
PEGINTERFERON AND RIBAVIRIN IN THE DUTCH ACUTE
HEPATITIS C IN HIV STUDY (DAHHS)
Sebastiaan Hullegie*, Mark Claassen, Guido van den Berk,
Jan van der Meer, Dirk Posthouwer, Fanny Lauw, Joop Arends,
Peter Koopmans, Clemens Richter, Arne van Eeden, Wouter Bierman,
Eliane Leyten, Bart Rijnders, The Netherlands
SOFOSBUVIR CONTAINING REGIMES TO PATIENTS WITH
HCV GENOTYPE 3 INFECTION. A SCANDINAVIAN REAL-
LIFE EXPERIENCE.
Olav Dalgard*, Nina Weis, Geir Noraberg, Kjetil Isaksen, Anne Oevrehus,
Mette Skalshøj Skjær, Olav Weiland, Norway
Vienna, Austria • April 22–26, 2015 361
LP45 END IN THE DAMAGED LIVER
Lara Campana*, Antonella Pellicoro, Rebecca Aucott, Stephen Greenalgh,
LP46 Steven Anderton, John P. Iredale, The United Kingdom
LP47 THE HEPATITIS B VIRUS (HBV) SURFACE ANTIGEN
LP48 IMPEDES HEPADNAVIRAL REPLICATION-DEPENDENT
LP49 INTERFERON RESPONSES IN A HBV TRANSGENIC MOUSE
MODEL
Catherine I. Real, Mengji Lu, Markus Hossbach, Jochen Deckert,
Kerstin Jahn-Hofmann, Ludger M. Ickenstein, Matthias J. John,
Martin Trippler, Kathrin Gibbert, Ulf Dittmer, Hans-Peter Vornlocher,
Reinhold Schirmbeck, Guido Gerken, Joerg F. Schlaak, Ruth Broering*,
Germany
OCCULT HBV IS HIGHLY PREVALENT IN PATIENTS WITH
INTRAHEPATIC CHOLANGIOCARCINOMA AND IT IS
DETECTED AS BOTH FREE EPISOMAL AND INTEGRATED
DNA
Teresa Pollicino*, Cristina Musolino, Gianluca Tripodi, Marika Lanza,
Giuseppina Raffa, Carlo Saitta, Salvatore Benfatto, Concetta Beninati,
Giuseppe Navarra, Pietro Invernizzi, Domenico Alvaro,
Giovanni Raimondo, Italy
EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE TO
PREVENT VERTICAL TRANSMISSION IN MOTHERS WITH
LAMIVUDINE-RESISTANT HBV
Jinfeng Liu*, Jing Wang, Furong Cao, Taotao Yan, Caijing Qi,
Tianyan Chen,Yingren Zhao, China
SVR12 RESULTS AFTER 12-WEEKS BOCEPREVIR,
PEGINTERFERON AND RIBAVIRIN IN THE DUTCH ACUTE
HEPATITIS C IN HIV STUDY (DAHHS)
Sebastiaan Hullegie*, Mark Claassen, Guido van den Berk,
Jan van der Meer, Dirk Posthouwer, Fanny Lauw, Joop Arends,
Peter Koopmans, Clemens Richter, Arne van Eeden, Wouter Bierman,
Eliane Leyten, Bart Rijnders, The Netherlands
SOFOSBUVIR CONTAINING REGIMES TO PATIENTS WITH
HCV GENOTYPE 3 INFECTION. A SCANDINAVIAN REAL-
LIFE EXPERIENCE.
Olav Dalgard*, Nina Weis, Geir Noraberg, Kjetil Isaksen, Anne Oevrehus,
Mette Skalshøj Skjær, Olav Weiland, Norway
Vienna, Austria • April 22–26, 2015 361
